A Phase I/II Open-label Multicenter Study of AT7519M Alone and in Combination With Bortezomib in Patients With Previously Treated Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 25 Sep 2016
At a glance
- Drugs AT 7519 (Primary) ; Bortezomib
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Astex Therapeutics
- 07 Aug 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jun 2014 Planned End Date changed from 1 Oct 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 24 Jun 2014 Planned primary completion date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History